Researchers are evaluating whether ADXS 11-001 vaccination prior to transoral surgery will improve outcomes for patients with HPV-positive oropharyngeal cancer.
Researchers are evaluating whether DPX-E7 vaccination is safe and will improve outcomes among patients with HPV-positive head and neck, cervical, or anal cancer.
Findings suggest that TORS is a promising strategy for improving swallowing function in patients with OPSCC, without compromising disease-free survival.
The ICON-S developed a TNM classification specific to human papillomavirus (HPV)-related oropharyngeal cancer.
Detection of human papillomavirus (HPV)-16 in the oral cavity may be associated with 22-times increased risk of oropharyngeal squamous cell carcinoma.
Human papillomavirus 16 (HPV16)-positive patients with oropharyngeal squamous cell cancer (OPSCC) survive longer than HPV-negative patients.
In veterans, oropharyngeal squamous cell carcinoma (SCC) is associated with traditional carcinogens and poor clinical outcomes.
Human papillomavirus (HPV) type 16 DNA in oral rinses is common at diagnosis, but rare after treatment for HPV oropharyngeal carcinoma (OPC).
Several factors associated with the burdensome Medicare cost of oral and pharyngeal cancer in older patients.
The quadrivalent human papillomavirus (HPV4) vaccine appears to be cost-effective for the prevention of oropharyngeal cancer (OPC).
The Eastern Cooperative Oncology Group (ECOG) conducted a trial to investigate whether treatment deintensification was feasible in patients with HPV-associated cancer.
Mixed views in relation to explaining causal role of human papillomavirus (HPV) in oropharyngeal cancer.
Oral malignancies can be associated with increased pain, but current research suggests that a cannabis-based spray may reduce this morbidity.
For patients with oropharynx cancer, HPV positivity is associated with improved survival after disease progression.
Two-thirds of surveyed adults reported being not very or not at all knowledgeable about head and neck cancer.
CHICAGO, IL—Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients' quality of life.
ANAHEIM, CALIFORNIA—Among oropharyngeal patients receiving radiotherapy, gabapentin improved pain management and reduced weight loss, which potentially prevents the need for placement of a gastrostomy tube.
Oral HPV, HPV16 DNA commonly detected in patients with oropharyngeal cancer, but not their partners.
Most oropharyngeal cancers in the United States diagnosed between 1995 and 2005 were positive for human papillomavirus, specifically HPV 16 or 18.
Patients with HPV-positive OPSCC report different symptoms than those with HPV-negative OPSCC, which may have an effect on how early the disease is diagnosed.
From 1973 to 2009, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) increased in patients younger than 45 years.
Death rates from cancer continue to decline in the United States
There is currently insufficient evidence to weigh the benefits and harms of PCP screening of asymptomatic adults for oral cancer.
Head and neck cancers have increased 60% since 1973.
In plasma samples obtained prior to diagnosis, the presence of human papillomavirus type 16 E6 antibodies was more likely to be detected in patients with oropharyngeal cancer than in controls.
The incidence of HPV-negative oropharyngeal cancers (OPC) is in decline, but rates of HPV-positive OPC are increasing with no sign of abating.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy